SCHEMBL4764104

SCHEMBL4764104

Cc1ccc(-c2cc(CO)ccn2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.47
LOXL2 Q9Y4K0 3/20 0.46
KDM1A O60341 3/20 0.45
HDAC1 Q13547 3/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HDAC6 Q9UBN7 1/20 0.43
MAP2K4 P45985 2/20 0.42
CCR1 P32246 1/20 0.41
CCR5 P51681 1/20 0.41
CCR8 P51685 1/20 0.41
PIM1 P11309 1/20 0.40
TGFBR1 P36897 1/20 0.40
SREBF2 Q12772 2/20 0.39
SREBF1 P36956 1/20 0.39
PDCD1 Q15116 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
KRAS P01116 1/20 0.38
MAOA P21397 1/20 0.38
DYRK1A Q13627 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4772868 0.82 LOXL2 (0.43) LOXL2KDM1AHDAC1MEN1KMT2A
SCHEMBL12970082 0.82 CCR1 (0.55) LOXL2KDM1AHDAC1MEN1KMT2A
SCHEMBL4772393 0.82 RECQL (0.56) RECQLLOXL2MEN1KMT2APIM1
SCHEMBL14310545 0.82 LOXL2 (0.50) RECQLLOXL2KDM1AHDAC1MEN1
SCHEMBL4772524 0.82 LOXL2 (0.50) RECQLLOXL2KDM1AHDAC1HDAC6
SCHEMBL4492835 0.82 RECQL (0.47) RECQLLOXL2MEN1KMT2APIM1
SCHEMBL5468413 0.81 CCR1 (0.65) RECQLMEN1KMT2AMAP2K4CCR1
SCHEMBL995901 0.81 ASIC3 (0.53) RECQLLOXL2KDM1AHDAC1HDAC6
SCHEMBL13568576 0.81 APP (0.49) RECQLLOXL2MEN1KMT2A
SCHEMBL13568603 0.81 RECQL (0.47) RECQLLOXL2MEN1KMT2APIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1400513-B1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND KOWA CO (JP) 2008-01-09 EP disclosed
EP-1400513-B1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND KOWA CO (JP) 2008-01-09 EP disclosed
EP-1400513-A1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND Kowa Co., Ltd. (JP) 2004-03-24 EP disclosed
US-6552188-B2 Inhibit cell adhesion and cell infiltration; useful treating asthma, allergies, rheumatic diseases, arteriosclerosis, and inflammation; 2-(3,4,5-trimethoxyphenyl),4-((4-substituted piperazin-1-yl)methyl)pyridine compounds KOWA CO., LTD. (JP) 2003-04-22 US disclosed
US-20030022887-A1 Unsymmetrical cyclic diamine compound KOWA CO., LTD. (JP) 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022887-A1 Unsymmetrical cyclic diamine compound H1-0, DDAH1, AOC1 RECQL 1199/4885LOXL2 4426/4885KDM1A 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.